We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk, Novartis Settle Patent Dispute Over Diabetes Blockbuster Victoza
Novo Nordisk, Novartis Settle Patent Dispute Over Diabetes Blockbuster Victoza
Novo Nordisk has settled a patent dispute with Novartis over allegations that the Swiss company infringed on patents for Victoza (liraglutide), Novo Nordisk’s blockbuster type 2 diabetes drug.